⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVO News
Novo-Nordisk A/S
IgA Nephropathy Clinical Trial Space Intensifies with 25+ Companies in Active Development | DelveInsight
globenewswire.com
NVS
VRTX
BIIB
VTRS
AZN
IONS
TAK
ARWR
BHVN
NVO
LLY
LXRX
XRTX
REGN
FMS
MDT
AMPH
DRCT
BMRC
MAZE
Parker Waichman LLP Files Lawsuit on behalf of Ohio Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Ozempic
prnewswire.com
NVO
Zealthy Expands Online Access to Ozempic Evaluations and Insurance Support for Eligible Patients With Type 2 Diabetes
globenewswire.com
NVO
Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda
globenewswire.com
ABBV
ALNY
ASTL
AZN
BIIB
BMY
CSL
LLY
GILD
GSK
MRK
NVS
NVO
PFE
REGN
SNY
SUN
TEVA
UPST
VRTX
Novo Nordisk A/S - share repurchase programme
globenewswire.com
NVO
GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand
accessnewswire.com
LEXX
NVO
LLY
Novo Nordisk A/S - share repurchase programme
globenewswire.com
NVO
Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK
globenewswire.com
NVO
Planisware unveils latest AI innovations at its annual Exchange26 EMEA conference
globenewswire.com
NVO
Parker Waichman LLP Files Lawsuit on behalf of Massachusetts Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Wegovy
prnewswire.com
NVO